Dry eye: have we found the perfect diagnostic?

Article

With the development of new instruments that accurately and easily measure tear osmolarity, the authors believe that this test should become the 'gold standard' for diagnosing dry eye disease in both the routine clinical and research settings.

Key Points

Dry eye disease is usually a symptomatic disorder that ranges in severity from mildly irritating to severely disabling. The main aim of diagnosis is to distinguish dry eye disease from other ocular surface diseases with similar symptoms, such as ocular allergy, surface toxicity and chronic, low-grade infection. Tests should also be performed to establish the impact of the disease on a patient's quality of life and to quantify disease severity in order to guide therapeutic choices.1 However, its diagnosis has always been difficult, especially in the early stages of the disease, because of the lack of availability of an agreed standard diagnostic test.

Tear hyperosmolarity is central to the dry eye disease process and the value of measuring tear osmolarity in the diagnosis of dry eye disease is well established. However, tear osmolarity measurement has been restricted to research settings because conventional testing systems are complex, costly, time-consuming, or need larger tear samples than are obtainable in some forms of dry eye.

With the development of new instruments that accurately and easily measure tear osmolarity, we believe that this test should become the 'gold standard' for diagnosing dry eye disease in both the routine clinical and research settings.

Some eye practitioners use symptoms as the criterion for diagnosing dry eye. The administration of a structured questionnaire to patients is certainly a valuable tool for screening patients with dry eye disease.1 However, symptoms alone are inadequate for the differential diagnosis of dry eye because the same symptoms can be experienced with a range of ocular surface conditions and tear film disorders.2,3 In fact, the 2007 International Dry Eye Workshop (DEWS), in which we both participated, recommended that symptomatology questionnaires should be used in combination with objective clinical measures of dry eye status.1

The role of tear hyperosmolarity

A number of theories have been put forward to explain the mechanism(s) underlying the break-up of the tear film. We considered these various theories during the 2007 DEWS meeting and concluded that tear hyperosmolarity is the central mechanism causing ocular surface inflammation, damage and symptoms.1 Acknowledging that our understanding of the etiopathology of dry eye is rapidly advancing, current concepts relevant to tear hyperosmolarity can be summarized as follows:

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.